Clinical trials: Baseline
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Dengue Fever
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to…
- Trial name
- CYD00082 (NCT04113330)
- Where
- Colombia
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Myocardial Infarction
Safety and Efficacy of SeeMore (TM) in Heart Patients
This study will examine the safety and effectiveness of a manganese-based agent called SeeMore (EVP 1001-1 Injection) for enhancing magnetic resonance imaging (MRI) in patients who have previously had a heart attack.
- Trial name
- NCT00881075
- Testing
- SeeMore(TM)
- Volunteers
- 24 people
- Sponsor
- Eagle Vision Pharmaceutical Corp.
Reduction in Abdominal Circumference
Effectiveness Study of the UltraShape® Contour I-Y for Non-Invasive Reduction in Abdominal Circumference
The UltraShape® Contour I- Y system uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
- Trial name
- NCT01609699
- Testing
- Treatment with Contour I-Y system
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UltraShape
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase…
- Trial name
- Pangeia-2 (NCT06417801)
- Where
- 6 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Idiopathic Short Stature
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
The evaluation of a standardized diagnostic test to predict the growth response in a 1 year trial with Growth Hormone (GH) treatment (carried out in the context of regular patient care) in non GH deficient short children with low…
- Trial name
- NCT01438801
- Testing
- Nutropin [Somatropin (rDNA origin) for injection]
- Sponsor
- Ipsen
Infertility
A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation
This is a phase IV non-interventional, multicentric observational study to evaluate the baseline follicle stimulating hormone (FSH) levels, ovarian volume, antral follicle count (AFC) and age as prognostic factors of the outcome…
- Trial name
- NCT01196143
- Where
- Greece
- Volunteers
- 356 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Fabry Disease, Lysosomal Storage Diseases
A Fabry Disease Gene Therapy Study
This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.
- Trial name
- MARVEL1 (NCT04040049)
- Testing
- FLT190
- Where
- 13 sites in United States, Austria and 5 more
- Volunteers
- 3 people
- Sponsor
- Spur Therapeutics
Acne
A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.
This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.
- Trial name
- NCT06602284
- Testing
- Dermapen 4™
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Equipmed USA LLC
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00881842
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Multiple Sclerosis
Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies
This retrospective, observational cohort study used administrative claims data contained in the International Business Machines (IBM)® Truven Marketscan® Research Databases to describe demographic, clinical, and treatment…
- Trial name
- NCT06459232
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Novartis
GERD
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with…
- Trial name
- NCT00242736
- Testing
- Esomeprazole
- Where
- 25 sites in United States
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Angiokeratomas
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
- Trial name
- LOTU (NCT07552077)
- Testing
- PTX-022
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Palvella Therapeutics, Inc.
COVID-19
A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers
This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at…
- Trial name
- NCT04405466
- Testing
- Blood sampling, Throat swab
- Where
- Germany
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- Miltenyi Biomedicine GmbH
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH